High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia M. Lafaurie, J. Lapalu, E.

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome J. Guinea, M. Torres-Narbona, P.

Gut bacterial microbiota and obesity

I.J. Schalk Clinical Microbiology and Infection

Approach to diagnosis of infective endocarditis

S. Wagenpfeil, A. Neiss, K. Banz, P. Wutzler

Clinical Microbiology and Infection

Herpes zoster in non-hospitalized children

Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study N. Lerolle, E. Raffoux, G. Socie, S. Touratier,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

R. Cantón Clinical Microbiology and Infection

P. Nordmann, L. Poirel Clinical Microbiology and Infection

Public health significance of invasive mosquitoes in Europe

Louis Pasteur, from crystals of life to vaccination

Chlamydia trachomatis infections in heterosexuals attending sexually transmitted disease clinics in Slovenia D. Kese, M. Maticic, M. Potocnik Clinical.

Increased incidence of nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008–2013 L.E.B. Nabarro, R.A. Lever, M. Armstrong,

Trends in length of stay, mortality and readmission among patients with community- acquired bacteraemia M. Søgaard, R.W. Thomsen, R.B. Bang, H.C. Schønheyder,

Clinical Microbiology and Infection

Clinical Microbiology and Infection

Vector control: a cornerstone in the malaria elimination campaign

J.P. Donnelly, B.E. De Pauw Clinical Microbiology and Infection

A. Solé, P. Morant, M. Salavert, J. Pemán, P. Morales

Sofie Arens, Jan Verhaegen, Ludo Verbist

Training for the infectious diseases speciality in Norway

G. Höffken Clinical Microbiology and Infection

High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia M. Lafaurie, J. Lapalu, E.

B. Gordts Clinical Microbiology and Infection

Laboratory diagnosis and biosafety issues of biological warfare agents

Elements of design: the knowledge on which we build

Levofloxacin in the treatment of ventilator-associated pneumonia

J. Bodilsen, C. T. Brandt, A. Sharew, M. Dalager-Pedersen, T

Metagenomics and probiotics

Laboratory diagnosis of Clostridium difficile disease

Systematic review of antibiotic consumption in acute care hospitals

Incidence of Hajj-associated febrile cough episodes among French pilgrims: a prospective cohort study on the influence of statin use and risk factors

Update on antifungal resistance in Aspergillus and Candida

M. Bassetti, M.P. Molinari, M. Mussap, C. Viscoli, E. Righi

Abstracts cont. Clinical Microbiology and Infection

Experience with the Platelia Candida ELISA for the diagnosis of invasive candidosis in neonatal patients S. Oliveri, L. Trovato, P. Betta, M.G. Romeo,

Current experience in treating invasive zygomycosis with posaconazole

Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,

Clinical infection services—the Leiden experience

Sequential time to positivity of blood cultures can be a predictor of prognosis of patients with persistent Staphylococcus aureus bacteraemia M.-S. Hsu,

An after-hours clinical liaison blood culture service—is it worth it?

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Listeriosis: a resurgent foodborne infection

Clinical Microbiology and Infection

Changing pattern of candidaemia 2001–2006 and use of antifungal therapy at the University Hospital of Vienna, Austria E. Presterl, F. Daxböck, W. Graninger,

Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis J. Gavaldá, T. Martín, P.

W. Eugene Sanders, Christine C. Sanders

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

Z. Erjavec, H. Kluin-Nelemans, P.E. Verweij

The atypical pneumonias: clinical diagnosis and importance

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre R.R. Laffer, P. Graber, P.E. Ochsner, W. Zimmerli

Serum ferritin levels in West Nile encephalitis

Modelling during an emergency: the 2009 H1N1 influenza pandemic

A. Manzur, F. Gudiol Clinical Microbiology and Infection

Update on invasive aspergillosis: clinical and diagnostic aspects

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Three years experience of real-time PCR for the diagnosis of Q fever

J.A. Pérez-Molina, F. Fernández Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia M. Lafaurie, J. Lapalu, E. Raffoux, B. Breton, C. Lacroix, G. Socié, R. Porcher, P. Ribaud, S. Touratier, J.-M. Molina Clinical Microbiology and Infection Volume 16, Issue 8, Pages 1191-1196 (August 2010) DOI: 10.1111/j.1469-0691.2009.03050.x Copyright © 2010 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Empirical antifungal therapies (EAFT) and outcome during 56 episodes of febrile neutropenia after chemotherapy among 49 patients. *Switch from liposomal amphotericin B (AmB) to caspofungin (n = 6) because of toxicity (renal insufficiency, n = 4) or side effects (infusion related chills, n = 2). **Suspected invasive aspergillosis (n = 2), hospital discharge (n = 2). Clinical Microbiology and Infection 2010 16, 1191-1196DOI: (10.1111/j.1469-0691.2009.03050.x) Copyright © 2010 European Society of Clinical Infectious Diseases Terms and Conditions